The Current Ratio as of November 2024 (TTM) for Amicus Therapeutics, Inc. (FOLD) is 3.15

According to Amicus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.15. This represents a change of 6.72% compared to the average of 2.95 of the last 4 quarters.

Amicus Therapeutics, Inc. (FOLD) Historical Current Ratio (quarterly & annually)

How has FOLD Current Ratio performed in the past?

The mean historical Current Ratio of Amicus Therapeutics, Inc. over the last ten years is 4.42. The current 3.15 Current Ratio has changed 7.03% with respect to the historical average. Over the past ten years (40 quarters), FOLD's Current Ratio was at its highest in in the June 2015 quarter at 21.60. The Current Ratio was at its lowest in in the June 2017 quarter at 2.39.

Amicus Therapeutics, Inc. (FOLD) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Amicus Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Amicus Therapeutics, Inc. (FOLD) Average Current Ratio

How has FOLD Current Ratio performed in the past?

The current Current Ratio of Amicus Therapeutics, Inc. (FOLD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Amicus Therapeutics, Inc. (FOLD) Current Ratio vs. Peers

How is FOLD’s Current Ratio compared to its peers?

Amicus Therapeutics, Inc.’s Current Ratio is greater than Incyte Corporation (1.87), less than Denali Therapeutics Inc. (9.98), less than argenx SE (8.53), less than Harmony Biosciences Holdings, Inc. (3.24), greater than Ultragenyx Pharmaceutical Inc. (2.81), less than Crinetics Pharmaceuticals, Inc. (16.38), less than Arvinas, Inc. (4.17), less than Revolution Medicines, Inc. (14.24), less than Kura Oncology, Inc. (11.47), less than Mineralys Therapeutics, Inc. (8.55), less than Legend Biotech Corporation (4.98), less than Cytokinetics, Incorporated (9.28), less than Inhibrx Biosciences, Inc. (4.70), less than DICE Therapeutics, Inc. (38.14), less than Edgewise Therapeutics, Inc. (26.35), less than Karuna Therapeutics, Inc. (19.31), less than Dyne Therapeutics, Inc. (17.02), less than Mereo BioPharma Group plc (6.10), less than Blueprint Medicines Corporation (3.32), less than Agios Pharmaceuticals, Inc. (8.99), less than Day One Biopharmaceuticals, Inc. (14.62), less than BioMarin Pharmaceutical Inc. (4.27),

Build a custom stock screener for Amicus Therapeutics, Inc. (FOLD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amicus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Amicus Therapeutics, Inc. (FOLD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Amicus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.